Strain Data Sheet
RBRC02344
Strain Information | |
|---|---|
| Image |  |
| BRC No. | RBRC02344 |
| Type | Targeted Mutation |
| Species | Mus musculus |
| Strain name | FVB.129P2-Nf2<tm2Gth> |
| Former Common name | Nf2flox2 (FVB) |
| H-2 Haplotype | |
| ES Cell line | |
| Background strain | FVB/NJcl |
| Appearance | albino [A/A B/B c/c D/D P/P] |
| Strain development | Developed by Drs. Marco Giovannini and Gilles Thomas in INSERM at 1988. Strain of Origin: 129P2/OlaHsd-Hprt1<b-m3> via HM-1 ES cell line. FVB background. |
| Strain description | Nf2, neurofibromatosis 2 is a tumor suppressor gene encoding a putative cytoskeletal associated protein. This conditional knockout mice have a loxP-flanked Nf2 allele. Conditional Nf2 deficient mice can be generated by crossing with tissue-specific Cre mice. |
| Colony maintenance | Sibling Mating (Homozygote x Homozygote, Heterozygote)Homozygous mutant mice are viable and fertile. |
| References | Genes Dev., 14, 1617-1630 (2000). 10887156 |
Health Report | |
|---|---|
| Examination Date / Room / Rack | 2024/02/26Room:4-BRack:K 2023/11/27Room:4-BRack:K 2023/08/28Room:4-BRack:K 2023/05/29Room:4-BRack:K 2023/02/27Room:4-BRack:K 2022/11/29Room:4-BRack:K 2022/08/29Room:4-BRack:K 2022/05/31Room:4-BRack:K |
Gene | |
|---|---|
| Gene info | Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter Nf2neurofibromatosis 211Nf2<tm2Gth>targeted mutation 2, Gilles Thomasmerlin, moesin-ezrin-radixin-like protein, schwannomin Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter loxPphage P1 loxP11loxP Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter loxPphage P1 loxP11loxP |
Ordering Information | |
|---|---|
| Donor DNA | phage P1 loxP sites, mouse Nf2 genomic DNA |
| Research application | Cre/loxP system |
| Specific Term and Conditions | In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Genes Dev., 14, 1617-1630 (2000).In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use. RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention. In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters. |
| Depositor | Marco Giovannini (INSERM) |
| Strain Status |  Live mice Frozen embryos |
| Strain Availability | Cryopreserved embryos (within 1 month) Live mouse (1 to 3 months) |
| Additional Info. | Necessary documents for ordering:
Genotyping protocol -PCR- |
BRC mice in Publications |
|---|
Ahmad I, Fernando A, Gurgel R, Jason Clark J, Xu L, Hansen MR. Merlin status regulates p75(NTR) expression and apoptotic signaling in Schwann cells following nerve injury. Neurobiol Dis 82 114-122(2015) 26057084 |